Citigroup’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.99M | Sell |
6,000
-18,000
| -75% | -$6.13M | ﹤0.01% | 2667 |
|
|
2025
Q4 | $9.54M | Hold |
24,000
| – | – | ﹤0.01% | 1571 |
|
|
2025
Q3 | $10.9M | Buy |
+24,000
| New | +$9.77M | ﹤0.01% | 1419 |
|
|
2025
Q2 | – | Sell |
-50,000
| Closed | -$13.5M | – | 5639 |
|
|
2025
Q1 | $13.5M | Buy |
50,000
+20,000
| +67% | +$5.14M | 0.01% | 1180 |
|
|
2024
Q4 | $7.06M | Sell |
30,000
-600
| -2% | -$158K | ﹤0.01% | 1651 |
|
|
2024
Q3 | $8.42M | Buy |
30,600
+19,300
| +171% | +$5.02M | ﹤0.01% | 1438 |
|
|
2024
Q2 | $2.75M | Sell |
11,300
-44,700
| -80% | -$7.06M | ﹤0.01% | 2083 |
|
|
2024
Q1 | $8.37M | Buy |
56,000
+31,000
| +124% | +$5.17M | 0.01% | 1350 |
|
|
2023
Q4 | $4.79M | Buy |
25,000
+5,100
| +26% | +$869K | ﹤0.01% | 1624 |
|
|
2023
Q3 | $3.52M | Buy |
+19,900
| New | +$3.8M | ﹤0.01% | 1620 |
|
|
2023
Q1 | – | Sell |
-52,000
| Closed | -$12.4M | – | 5464 |
|
|
2022
Q4 | $12.4M | Buy |
52,000
+17,200
| +49% | +$3.67M | 0.01% | 1024 |
|
|
2022
Q3 | $6.97M | Buy |
+34,800
| New | +$6.64M | 0.01% | 1355 |
|
|
2022
Q2 | – | Sell |
-18,400
| Closed | -$3M | – | 6201 |
|
|
2022
Q1 | $3M | Buy |
+18,400
| New | +$2.8M | ﹤0.01% | 2008 |
|
|
2021
Q1 | – | Sell |
-16,800
| Closed | -$2.18M | – | 6201 |
|
|
2020
Q4 | $2.18M | Sell |
16,800
-2,800
| -14% | -$374K | ﹤0.01% | 2770 |
|
|
2020
Q3 | $2.85M | Buy |
19,600
+600
| +3% | +$85.3K | ﹤0.01% | 2341 |
|
|
2020
Q2 | $2.81M | Sell |
19,000
-1,400
| -7% | -$189K | ﹤0.01% | 2415 |
|
|
2020
Q1 | $2.22M | Buy |
20,400
+2,400
| +13% | +$277K | ﹤0.01% | 2379 |
|
|
2019
Q4 | $2.07M | Buy |
18,000
+9,500
| +112% | +$947K | ﹤0.01% | 2925 |
|
|
2019
Q3 | $684K | Buy |
8,500
+1,600
| +23% | +$127K | ﹤0.01% | 4039 |
|
|
2019
Q2 | $501K | Sell |
6,900
-7,000
| -50% | -$537K | ﹤0.01% | 4426 |
|
|
2019
Q1 | $1.3M | Sell |
13,900
-22,000
| -61% | -$1.84M | ﹤0.01% | 3114 |
|
|
2018
Q4 | $2.62M | Sell |
35,900
-24,500
| -41% | -$1.88M | ﹤0.01% | 2417 |
|
|
2018
Q3 | $5.29M | Buy |
60,400
+28,400
| +89% | +$2.86M | ﹤0.01% | 1814 |
|
|
2018
Q2 | $3.15M | Buy |
32,000
+8,800
| +38% | +$873K | ﹤0.01% | 2269 |
|
|
2018
Q1 | $2.76M | Sell |
23,200
-40,900
| -64% | -$5.27M | ﹤0.01% | 2318 |
|
|
2017
Q4 | $8.14M | Sell |
64,100
-13,600
| -18% | -$1.71M | 0.01% | 1436 |
|
|
2017
Q3 | $9.13M | Buy |
77,700
+43,300
| +126% | +$3.7M | 0.01% | 1296 |
|
|
2017
Q2 | $2.74M | Buy |
34,400
+19,300
| +128% | +$1.23M | ﹤0.01% | 2259 |
|
|
2017
Q1 | $774K | Sell |
15,100
-67,500
| -82% | -$3.12M | ﹤0.01% | 3476 |
|
|
2016
Q4 | $3.09M | Buy |
82,600
+68,600
| +490% | +$2.87M | ﹤0.01% | 2403 |
|
|
2016
Q3 | $949K | Buy |
14,000
+3,100
| +28% | +$219K | ﹤0.01% | 3274 |
|
|
2016
Q2 | $605K | Buy |
10,900
+2,600
| +31% | +$164K | ﹤0.01% | 3454 |
|
|
2016
Q1 | $521K | Buy |
8,300
+2,400
| +41% | +$160K | ﹤0.01% | 4071 |
|
|
2015
Q4 | $555K | Sell |
5,900
-200
| -3% | -$18.5K | ﹤0.01% | 3744 |
|
|
2015
Q3 | $490K | Buy |
6,100
+800
| +15% | +$88.9K | ﹤0.01% | 3768 |
|
|
2015
Q2 | $635K | Sell |
5,300
-15,500
| -75% | -$1.85M | ﹤0.01% | 3491 |
|
|
2015
Q1 | $2.17M | Buy |
20,800
+5,800
| +39% | +$588K | ﹤0.01% | 2405 |
|
|
2014
Q4 | $1.46M | Buy |
+15,000
| New | +$1.39M | ﹤0.01% | 2759 |
|
Other funds holding ALNY
VPM
VCM
Citigroup's ALNY Position: Q1 2026 in Review
Citigroup increased its Alnylam Pharmaceuticals (ALNY) stake by 53% in Q1 2026, buying an estimated $30.9M and bringing the position to 263,375 shares worth $87.1M. The position accounts for 0.04% of the portfolio, ranked #449.
Citigroup first reported a position in ALNY in Q2 2013 and has held it in 52 quarters since. The position peaked at $97.6M in Q2 2024. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Citigroup held 263,375 shares of Alnylam Pharmaceuticals worth $87.1M as of Q1 2026.
- Citigroup bought 90,813 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $30.9M.
- Alnylam Pharmaceuticals made up 0.04% of Citigroup's portfolio in Q1 2026, its #449 holding.
- Citigroup first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Citigroup's Alnylam Pharmaceuticals position peaked at $97.6M in Q2 2024.
- 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.